FDA Commissioner Makary Failed Pro-Life Voters by Enabling Unrestricted Abortion Pill Access
Source: https://www.facebook.com/americanspectator/. "Good Riddance, Marty | The American Spectator | USA News and Politics." May 15, 2026. spectator.org
The Gist
The author argues that FDA Commissioner Makary should have been fired because he refused to crack down on abortion pills despite safety concerns and pressure from pro-life groups. She claims he deliberately avoided studying the drugs' dangers and made them too easy to get online.
Conclusion
Marty Makary failed as FDA commissioner and deserved to be fired because he refused to restrict abortion pill access despite safety concerns and pro-life expectations
Premises
- Makary explicitly stated he doesn't think about the abortion pill or its safety restrictions
- Abortion pills have an 11% serious adverse event rate including sepsis, infection, and hemorrhaging
- Makary delayed safety studies by waiting for a new system not available until 2026-2027, effectively punting the issue
- He approved a new generic version of mifepristone, increasing market availability
- Current lax prescription system allows anyone to obtain pills online without in-person medical evaluation
- This system enables cross-state trafficking that nullifies pro-life state laws
- Men have used easily-obtained pills to poison women without their consent
Assumptions
- The FDA commissioner should prioritize restricting abortion pill access
- Abortion pills are inherently dangerous and should be heavily regulated
- Pro-life voters have legitimate expectations that Trump administration officials will advance anti-abortion policies
- State abortion bans should be enforceable and not circumventable through federal drug policy
- The FDA has both the authority and obligation to restrict abortion pill access for political/moral reasons